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Multiparametric magnetic resonance imaging of the prostate:
current concepts*
Ressonância magnética multiparamétrica da próstata: conceitos atuais
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Abstract
Resumo
Multiparametric MR (mpMR) imaging is rapidly evolving into the mainstay in prostate cancer (PCa) imaging. Generally, the examination
consists of T2-weighted sequences, diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) evaluation, and less often
proton MR spectroscopy imaging (MRSI). Those functional techniques are related to biological properties of the tumor, so that DWI
correlates to cellularity and Gleason scores, DCE correlates to angiogenesis, and MRSI correlates to cell membrane turnover. The combined
use of those techniques enhances the diagnostic confidence and allows for better characterization of PCa. The present article reviews and
illustrates the technical aspects and clinical applications of each component of mpMR imaging, in a practical approach from the urological
standpoint.
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O estudo por ressonância magnética multiparamétrica, ou funcional, vem evoluindo para se tornar o pilar fundamental no manejo diag-
nóstico de pacientes com câncer de próstata. Geralmente, o exame consiste em imagens pesadas em T2, difusão, realce dinâmico pelo
contraste (permeabilidade), e cada vez menos frequentemente espectroscopia de prótons. Tais técnicas funcionais relacionam-se com
propriedades biológicas do tumor, de modo que a difusão se relaciona com a celularidade e os escores de Gleason, a permeabilidade
se relaciona com a angiogênese, e a espectroscopia de prótons se relaciona com o metabolismo da membrana celular. O uso destas
técnicas em combinação aumenta a confiança diagnóstica e permite uma melhor caracterização do câncer de próstata. Este artigo tem
o objetivo de revisar e ilustrar os aspectos técnicos e as aplicações clínicas de cada componente do estudo de ressonância magnética
multiparamétrica da próstata, mediante uma abordagem prática.
Unitermos: Câncer de próstata; Ressonância magnética; Imagem por difusão; Realce dinâmico por contraste.
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examination (DRE), being both considered of limited accu-
racy in establishing a disease-specific diagnosis(1,2), and oc-
casionally leading to overdiagnosis and overtreatment(3,4).
In such a context, the diagnostic imaging modalities are
increasingly being used as a means to refine the detection
and staging of PCa, and to ultimately provide a better treat-
ment selection. Consequently, there has been a constant in-
crease in the interest of the radiological community for pros-
tate imaging modalities, with many studies also recently
published in Brazil(5–8). Among those modalities, magnetic
resonance (MR) imaging stands out as the most robust and
the one that is better related to the clinical outcomes involved
on the management of PCa. This review evaluates the role
of prostate MR imaging and its functional techniques on the
detection, staging and risk assessment of PCa.
MAGNETIC RESONANCE IMAGING
MR imaging is an imaging modality that does not in-
volve ionizing radiation, and provides high resolution im-
ages with excellent soft-tissue contrast. The contrast-media
employed is based on gadolinium chelates that show a better
immunoallergenic profile than iodinated media. However,
due to the risk of nephrogenic systemic fibrosis, caution
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INTRODUCTION
Prostate cancer (PCa) is the second most common cause
of cancer-related deaths in the male population. Currently,
the most important PCa screening tools are based on the evalu-
ation of prostate specific antigen levels and digital rectal
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should be taken on the use of gadolinium based agents in
patients with impaired renal function (i.e., creatinine clear-
ance < 30 ml/min/1.73 m2).
The examination is carried out with high field strength
scanners, with either 1.5 T or 3.0 T, using a pelvic surface
coil to maximize the signal in the region of interest. The use
of an endorectal coil is under debate, and most of the insti-
tutions currently relegate its use only for staging purposes,
according to a recent consensus statement(9). Taking into
account that hemorrhage is a potentially confounding factor
for misdiagnosis of PCa, an interval of 6–8 weeks between
the biopsy session and MR imaging examination is usually
advised in order to allow appropriate MR spectroscopy im-
aging (MRSI) acquisition and to prevent potential degrada-
tion of diffusion-weighted imaging (DWI) signal(10). The
patients are asked to refrain from sexual activities 72 hours
prior to the examination, in order to distend the seminal
vesicles and improve its visualization. At least a 4-hour fast-
ing interval is recommended, and the patients are instructed
to empty the bladder one hour before the examination. Also,
scopolamine (Buscopan®) is administered immediately be-
fore the examination, in order to attenuate peristalsis and
minimize motion artifacts.
As an imaging modality, MR imaging enables the as-
sessment of prostatic disease with a much higher spatial reso-
lution than any other technique. Consequently, MR imag-
ing has evolved as a powerful modality in the localization
and staging of PCa with a much better performance than DRE
or transrectal ultrasonography (TRUS)(11). Recent advances
combine functional techniques with the already established
anatomical imaging sequences based on T1- and T2-weigh-
ing, resulting in a multiparametric sequence protocol.
T2-weighted (T2w) imaging constitutes the backbone
of prostate imaging, providing anatomical details and show-
ing suspicious lesions with high spatial resolution. Among
the functional techniques, DWI(12), dynamic contrast en-
hancement (DCE) evaluation(13), and proton spectroscopy(14)
are part of routine clinical studies, and will be further ex-
plained throughout this article.
T2-weighted imaging findings
On T2w images in the axial plane(15) (Figure 1), the
normal peripheral zone demonstrates a homogeneous high-
signal intensity background with a “crescent” or “bullhorn
shape”. The prostatic capsule is defined by a thin, hypointense
line which is an important landmark for tumor staging. In
the absence of benign prostatic hyperplasia (BPH), the cen-
tral, transitional and periurethral zones are indistinguishable
from each other, thus being usually referred to in combina-
tion as “central” or “internal” gland. The healthy internal
gland is characterized by intermediate signal intensity on T2w
images. Encircling the central gland lays the “surgical cap-
sule”, a thin T2-hypointense layer that separates the inner
portion from the peripheral zone, and represents an impor-
tant landmark for BPH surgery.
At morphologic T2w images, PCa is characterized by
the presence of focal hypointense lesions, frequently with
nodular or oval shape, that either replace the normal
hyperintense signal of the peripheral zone, or the usual het-
erogeneous pattern of the internal gland(16) (Figure 2). This
finding is considered highly sensitive (> 90%) for the detec-
tion of PCa with Gleason scores of 7 or higher, but it should
Figure 1. MR imaging of the normal prostate. T2-weighted sequence in the axial
plane showing the prostate capsule (white arrowhead), the peripheral zone (ZP),
the surgical capsule (black arrowhead) and internal gland (asterisk).
Figure 2. Typical aspect of PCa in the
peripheral zone on T2-weighted MR im-
ages, showing as a hypointense nodu-
lar lesion at right, marked by arrow
heads in the axial (A) and sagittal (B)
planes.
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be known that this sensitivity drops significantly for Gleason
scores of 6 or lower. Most importantly, specificity of T2w
images alone is limited because hemorrhage, prostatitis,
scars, atrophy, post-radiation changes, post-cryoablation sta-
tus, and also hormone therapy may show up as focal low signal
intensities in the peripheral zone.
The diagnosis of PCa in the central zone by means of
conventional anatomical sequences poses an even greater
challenge, given the heterogeneity of the region and the wide
spectrum of changes attributable to BPH. Thus, a number
of criteria based on pattern-recognition algorithms have been
described(17), as follows: ill-defined homogeneous T2-hypoin-
tense focal lesion replacing the normal background (“erased
charcoal sign”); spiculated or ill-defined margins; anteriorly
located lesion; lenticular or spindle-like shape; loss of the T2-
hypointense contour of BPH nodules; loss of definition of
the surgical capsule; or signs of urethral invasion (Figure 3).
However, focal T2-hypointense areas may still be nor-
mally observed in the central gland as predominantly stro-
mal BPH, or either as prominence of the anterior fibromus-
cular stroma. Many different studies investigating the accu-
racy of conventional MR imaging in the detection of central
gland tumors have almost universally reported low sensitiv-
ity, low specificity and high interobserver variability(18).
Regarding local staging of PCa, the most important is-
sue is to differentiate between organ-confined disease (T1
and T2 stages) or locally advanced tumor, either as extra-
capsular extension (T3a) or as seminal vesicle invasion (T3b),
in order to choose the right treatment plan. The imaging
criteria for extracapsular extension include: neurovascular
bundle asymmetry; macroscopic tumor involvement of the
neurovascular bundle; focal bulging of the prostatic contour,
spiculation or irregularity of prostatic contour; obliteration
of the recto-prostatic angle; capsular retraction; contact of
the tumor focus with prostatic capsule wider than 1,0 cm;
and signs of capsular rupture with direct tumor extension to
the periprostatic fat(19,20) (Figure 4).
Findings that indicate seminal vesicle invasion include:
focal low signal intensity in the interior or along a seminal
Figure 4. T2-weighted MR images of the
prostate, showing typical findings of extra-
capsular tumor extension marked by arrow-
heads in the following examples: asymme-
try of the neurovascular bundle (A), tumor
involvement of the neurovascular bundle (B),
spiculated contour of the prostatic capsule
(C), and focal bulging on the contour of the
prostatic capsule (D).
Figure 3. Appearance of PCa in the internal gland on T2-weighted MR images in
the axial plane. It is noteworthy a hypointense area in the left internal gland (ar-
row), with indistinct contours, and signs of rupture of the surgical capsule (arrow-
head) extending into the adjacent peripheral zone.
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vesicle; T2 hypointense and enlarged seminal vesicle; T2
hypointense and enlarged ejaculatory duct; obliteration of
the bladder/prostate angle; and direct tumor extension form
the prostatic base to the seminal vesicle, this latter being one
the most positive predictive finding(21) (Figure 5).
The conventional anatomical MR imaging techniques
demonstrate a wide spectrum of reported sensitivities (13–
95%) and specificities (49–97%) among many different studies
for the detection of extracapsular extension. Similarly, the
sensitivities (23–80%) and specificities for the detection of
seminal vesicle invasion also show wide variation(17). There-
fore, those intrinsic limitations and variations in the results
of conventional techniques underscore the need for a multi-
parametric approach in prostate MR imaging, combining the
anatomical findings with those of the functional techniques.
Functional techniques
Proton spectroscopy
MR spectroscopic imaging (MRSI) has been widely used
as a biomarker for the detection and characterization of tu-
mors, including PCa(22). This technique aims to estimate the
concentration of certain substances and metabolites in a given
biological tissue, by means of MR imaging. The sampled
metabolites are represented by “spikes” or “peaks” in a spec-
trum, and the relationship among their concentrations is used
to establish the diagnosis (Figure 6).
Among the metabolites usually studied in prostate spec-
troscopy, citrate is found in high concentrations (> 60 mM)
in normal prostate epithelium and prostatic fluid, being also
observed in low concentrations in other locations of the
gland(23). Decreased levels of citrate are characteristically seen
in PCa, but also in areas of prostatitis and bleeding.
Choline represents a compound of cell membrane lip-
ids. Choline concentrations are generally elevated in PCa,
due to a higher cell-membrane turnover and an increased
cell-membrane surface/cell-volume ratio. A true increase in
choline peak is considered the spectral signature of malig-
nancy(24), but this may also be observed in prostatitis(25) to a
lesser extent.
Other metabolites in prostate MRSI include creatine,
which has no direct correlation with PCa and is primarily
used as a reference point; and polyamine, which is detected
only at 3 T and may be decreased in PCa.
However, considering that the spectrum does not provide
measurable absolute concentrations of metabolites, ratios and
comparisons are employed for the evaluation of metabolite
peaks. Among those, the most notorious ratio is calculated
by the formula (choline + creatine) / citrate. This ratio is used
Figure 6. Examples of MRSI pros-
tate spectra. A: Typical spectral
analysis of normal prostate tissue,
showing a high citrate (Ci) peak,
with a low choline (Cho) peak, and
the peak of creatine (Cr) used as
comparison parameter for the other
metabolites. On B, we observe the
spectral signature of typical ag-
gressive PCa, with a high choline
(Cho) peak and low citrate (Ci) lev-
els.
Figure 5. Signs of tumor exten-
sion to the seminal vesicles on T2-
weighted images, identified by ar-
rowheads. The key is to find hypo-
intense areas replacing the usual
hyperintense seminal vesicle, pro-
moting wall thickening and obliter-
ating their lumina, with either a dif-
fuse (A) or focal (B) appearance.
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as a marker for malignancy, especially for the peripheral
zone.
Although MRSI is promising as a high-specific method,
it significantly lacks sensitivity. A recent multicenter study
evaluated the incremental value of MRSI at 1.5 T over con-
ventional T2w images on the localization of PCa, and found
no benefit from MRSI information in terms of performance
and accuracy gain(14). The results of this important study,
combined with the very low interobserver agreement, the
considerably long acquisition time and the complexity of
post-processing, have led to the downgrading of MRSI to
the status of an ancillary and optional technique in most
centers that investigate prostate imaging.
Dynamic contrast enhancement (DCE)
DCE evaluation is a functional MR imaging technique
that enables the calculation of parameters that are intimately
related to the microvascular properties of tissue angiogen-
esis. In PCa, an increase in tumor vascularity expressed by
an enhancement pattern with intense and early contrast-me-
dia wash-in, followed by intense and early wash-out, unlike
normal peripheral zone tissue that shows slow, mild and pro-
gressive wash-in. Benign diseases, such as prostatitis and
BPH, may also lead to regional changes in the enhancement
pattern, although to lower extent(26) (Figure 7).
DCE evaluation is based on T1w sequences that are re-
peatedly acquired before, during and after contrast-media ad-
ministration, encompassing the whole prostate gland, with
a high temporal resolution. Multiple acquisitions are ob-
tained, up to 4–8 minutes. Then, images are post-processed
in specific applications, with either a semi-quantitative or a
quantitative approach, that usually enable the generation of
enhancement curves and color parametric maps for better
understanding by non-radiologists and better communica-
tion of the results. On those parametric maps, pixels have
colors according to a hemodynamic parameter analyzed (i.e.,
positive enhancement integral, wash-in rate, maximum in-
tensity pixel, ktrans, kep, etc.), and suspicious lesions mani-
fest as focal and asymmetric areas with high signal intensity
in the chosen color spectrum. Moreover, it is possible to
superimpose or fuse those color maps to the original T2w
images, thus increasing the degree of confidence by the ex-
act topographic correlation of anatomical and functional find-
ings (Figure 8).
Regardless of the choice between a semi-quantitative and
a quantitative model, DCE evaluation has shown strong evi-
dence for good performance in the diagnosis of PCa. It has
been demonstrated that, among others, DCE is significantly
better than conventional T2-weighted images in the local-
ization of tumor foci(27–29), and that it increases the accu-
racy in the detection of extracapsular extension and seminal
vesicle involvement by less experienced radiologists(30).
Thus, the use of DCE is definitely well indicated, and is a
fundamental part of multiparametric prostate MR imaging.
Figure 7. Signal intensity versus time
curve in a typical tumor lesion. The im-
age A represents the early arterial phase
of DCE evaluation, showing a focal area
of early contrast enhancement in the pe-
ripheral zone at right (outlined by the red
line). Normal appearing areas were also
outlined in the contralateral peripheral
zone (yellow) and internal gland (green).
The resulting curves (B) show that the
suspicious lesion (red curve) is charac-
terized by a high and steep rise (washin),
flowed by a marked decrease (washout),
with a significantly different behavior from
the other curves.
Figure 8. Semi-quantitative post-pro-
cessing of DCE. Image A represents the
parametric map generated from DCE
evaluation of the same patient of Figure
7, corresponding to the area under the
curve during the first minute (positive en-
hancement index – PEI). Note that on this
map, the suspected area cited in Figure
7 is coded in red (arrowheads), standing
out from the other portions of the pros-
tatic parenchyma. On B, one observes a
fusion between the DCE parametric map
and the T2-weighted sequence in the axial
plane, enabling better correlation of ana-
tomic and functional findings.
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Diffusion-weighted imaging (DWI)
DWI studies the random movement of water molecules
in different physical media, also known as “Brownian move-
ments”. In biological tissues, these movements are impeded
at different amounts by interactions with other molecules and
cell structures, or even by cellular density. Consequently, a
method that assesses water diffusion properties has ultimately
the potential to indirectly estimate information related to the
composition of a certain tissue, its cellular density, tissue
microperfusion, or even the viability of cell membranes(31).
In the clinical practice, those properties have taken DWI into
the category of a noninvasive imaging biomarker in oncol-
ogy, with many already proven applications in tumor detec-
tion, staging and response evaluation(32).
DWI is an imaging sequence that does not require con-
trast-media administration, and is carried out in approxi-
mately 5 minutes during prostate MRI examinations. The
sequence generates many image sets according to the num-
ber of diffusion factors or “b-factors” chosen. The scanner also
generates an apparent diffusion coefficient (ADC) map, which
is a set of images that enable the quantification of diffusion
properties. Thus, a lesion with impeded (or “restricted”)
diffusion appears as a hypointense area on the ADC map,
reflecting a low diffusion coefficient, or low “ADC values”.
The healthy prostate tissue is rich in tubular fluid-filled
structures, allowing for unimpeded diffusion of water mol-
ecules in their interior, manifesting by high ADC values. In
the majority of cases, the peripheral zone can be easily dis-
cerned from the central gland at DWI, owing to its homoge-
neously higher ADC values(33–35) (Figure 9). BPH leads to
the development of adenomatous nodules in the transitional
Figure 9. ADC map of the same patient from Figure 1, showing excellent distinc-
tion of the zonal anatomy. The normal peripheral zone (ZP) shows high ADC values
relative to the normal internal gland (GI). This fact probably explains the great utility
of DWI in detecting tumors in the peripheral zone, which present themselves as
foci of restricted diffusion (i.e., “dark lesions”) over a region with facilitated (i.e.,
“bright”) diffusion.
zone, which over time compress the central zone, making it
a difficult task to accurately define the zonal anatomy of the
central gland at MR imaging(15). This heterogeneity is also
manifested in water diffusion properties in BPH, being clas-
sically expressed at MR imaging as foci of low ADC values
interspersed with areas of high ADC values(36).
PCa is histologically characterized by a higher cell-den-
sity and a higher nucleus/cytoplasm ratio as compared with
the surrounding healthy prostate tissue, with substitution of
the glandular parenchyma by tumor cells. This causes im-
peded diffusion, with a marked reduction in the ADC values
relative to the healthy prostate tisue(12,37,38) (Figure 10).
Moreover, while well-differentiated tumors may in some
way maintain their tubular architecture, poorly-differentiated
or aggressive tumors exhibit prominent cell components, with
derangement of tubular architecture, and consequently gen-
erating potential differences in diffusion properties and ADC
measurements between those two categories(39–44).
Most studies have evaluated the usefulness of DWI in
the detection of PCa in the peripheral zone. Many of those
studies reported better performance for lesion detection in
comparison with T2w images, either by the use of DWI
alone, or in combination with conventional sequences(45).
Other studies have demonstrated that the combination of T2w
and DWI findings achieve a sensitivity in the range of 45–
89% and specificity of 61–97%, as compared with 74–85%
and 57–95% for DWI alone, or 25–87% and 57–92% for T2w
alone(36,45–52).
As regards the detection of lesions in the central gland,
DWI has the potential to complement T2w imaging find-
ings(53), since it is already known that, in PCa, the ADC
values are generally lower than those of the healthy central
gland(53,54) and of BPH nodules(36), but with smaller sensi-
tivity than for the peripheral zone.
In terms of local staging, the identification of minimal
extra-capsular extension requires high-resolution anatomi-
cal images(17), that usually overcome the spatial properties
of currently available DWI sequences. Conversely, the use-
fulness of DWI is already well demonstrated for the evalua-
tion of seminal vesicle involvement (SVI)(55,56), with higher
specificity (97%) and accuracy (96%) for the combination of
DWI and T2w, as compared with the specificity (87%) and
accuracy (87%) of T2w alone. Although so far unconfirmed
by the literature, in this same indication, there may also be
a role for the use of fused ADC maps and T2w images, which
may potentially add confidence to the diagnosis.
As regards the evaluation of tumor aggressiveness, histo-
pathology-based Gleason grading system remains as one of
the most important prognostic factors for disease-free survival
and for the determination of tumor clinical behavior(57–59).
However, it is also well known that, in a substantial number
of patients, the Gleason scores obtained from routine TRUS
biopsy specimens may be significantly underestimated in
relation to the final post-prostatectomy Gleason score(60,61).
Thus, among all other conventional and functional MR im-
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aging modalities, DWI is probably the one with the highest
potential to correlate with the degree of tumor aggressive-
ness, since the same factors that lead to a higher Gleason
score (e.g., high cellularity, loss of tubular architecture) also
promote restriction to water diffusion, and consequently low
ADC values(37).
Recently, a study developed by Bittencourt et al. dem-
onstrated a significant negative correlation between ADC
values in PCa and the respective Gleason scores(62) in pros-
tatectomy specimens. Moreover, this same study found that
DWI outperformed even the prostate biopsy specimens in
the estimation of PCa aggressiveness. Nevertheless, until this
moment, all of the studies have also observed a significant
overlap of ADC values along the different Gleason scores.
Therefore, it is postulated that the present role of DWI in
the evaluation of tumor aggressiveness is mainly the guid-
ance for collection of biopsy specimens 63) and the integra-
tion to risk assessment nomograms(64).
CONCLUSION
In conclusion, multiparametric prostate MR imaging is
now a reality in the clinical practice, with solid and well es-
tablished data regarding tumor detection and staging. DCE
and DWI are robust functional techniques that should be
included in every examination, increasing the accuracy and
reliability of the imaging findings provided by the anatomi-
cal T2w images. Large prospective studies are also ongoing,
aiming at correlating MR imaging findings with long-term
clinical outcomes, cancer screening and follow-up of active
surveillance patients.
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